No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib-Reference-Cited by-同舟云学术

No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib

Published:2017-01-12 Issue:5 Volume:143 Page:843-850
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Pfirrmann Markus,Evtimova Dobromira,Saussele Susanne,Castagnetti Fausto,Cervantes Francisco,Janssen Jeroen,Hoffmann Verena S.,Gugliotta Gabriele,Hehlmann Rüdiger,Hochhaus Andreas,Hasford Joerg,Baccarani Michele

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00432-016-2321-2.pdf

Reference24 articles.

1. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim D-W, Larson RA, Lipton JH, Mahon F-X, Martinelli G, Mayer J, Müller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saußele S, Schiffer C, Silver R, Simonsson B, Steegmann J-L, Goldman JM, Hehlmann R (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122(6):872–884. doi: 10.1182/blood-2013-05-501569

2. Bocchia M, Gentili S, Abruzzese E, Fanelli A, Iuliano F, Tabilio A, Amabile M, Forconi F, Gozzetti A, Raspadori D, Amadori S, Lauria F (2005) Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 365(9460):657–662. doi: 10.1016/S0140-6736(05)17945-8

3. Bonifacio M, Scaffidi L, Binotto G, De Marchi F, Maino E, Calistri E, Bonalumi A, Frison L, Marin L, Medeot M, De Matteis G, Fanin R, Semenzato G, Ambrosetti A, Tiribelli M (2015) Predictive factors of stable deep molecular response in chronic myeloid leukemia patients treated with standard dose imatinib: a study from the “Gruppo Triveneto LMC”. Blood 126(23):597 (abstract)

4. Brauer KM, Werth D, von Schwarzenberg K, Bringmann A, Kanz L, Grunebach F, Brossart P (2007) BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells. Cancer Res 67(11):5489–5497. doi: 10.1158/0008-5472.CAN-07-0302

5. Castagnetti F, Gugliotta G, Palandri F, Breccia M, Stagno F, Levato L, Fava C, Luciano L, Intermesoli T, Cedrone M, Carella AM, Cavazzini F, Turri D, Avanzini P, Pierri I, Lunghi M, Venturi C, Soverini S, Testoni N, Alimena G, Saglio G, Martinelli G, Pane F, Baccarani M, Rosti G (2012) The BCR-ABL1 transcript type does not influence the response and the outcome of chronic myeloid leukemia patients treated frontline with nilotinib. Blood 120(21):1680 (abstract)

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploration of treatment‐free remission in CML, based on molecular monitoring;Cancer Medicine;2023-12-22

2. European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia;Leukemia;2023-10-04

3. European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia;LEUKEMIA;2023

4. Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights;Cells;2023-06-23

5. Chronic-phase chronic myeloid leukemia: Incidence of BCR/ABL transcript and its correlation with presenting features, response to treatment, and survival;Leukemia Research Reports;2023